Aclaris Therapeutics, Inc. (ACRS)
6.54
+0.23
(+3.65%)
USD |
NASDAQ |
Aug 25, 16:00
6.54
0.00 (0.00%)
After-Hours: 16:08
Aclaris Therapeutics Total Assets (Quarterly) : 179.69M for June 30, 2026
Total Assets (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Assets (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 179.69M |
| March 31, 2026 | 198.72M |
| December 31, 2025 | 160.46M |
| September 30, 2025 | 175.53M |
| June 30, 2025 | 189.15M |
| March 31, 2025 | 198.09M |
| December 31, 2024 | 220.33M |
| September 30, 2024 | 182.39M |
| June 30, 2024 | 161.07M |
| March 31, 2024 | 174.06M |
| December 31, 2023 | 199.55M |
| September 30, 2023 | 218.35M |
| June 30, 2023 | 235.65M |
| March 31, 2023 | 229.70M |
| December 31, 2022 | 257.96M |
| September 30, 2022 | 267.63M |
| June 30, 2022 | 277.98M |
| March 31, 2022 | 226.53M |
| December 31, 2021 | 251.21M |
| September 30, 2021 | 263.49M |
| June 30, 2021 | 288.05M |
| March 31, 2021 | 161.40M |
| Date | Value |
|---|---|
| December 31, 2020 | 70.78M |
| September 30, 2020 | 71.90M |
| June 30, 2020 | 85.00M |
| March 31, 2020 | 96.81M |
| December 31, 2019 | 98.30M |
| September 30, 2019 | 160.42M |
| June 30, 2019 | 217.24M |
| March 31, 2019 | 253.18M |
| December 31, 2018 | 275.57M |
| September 30, 2018 | 176.18M |
| June 30, 2018 | 201.82M |
| March 31, 2018 | 220.62M |
| December 31, 2017 | 245.61M |
| September 30, 2017 | 261.39M |
| June 30, 2017 | 176.81M |
| March 31, 2017 | 166.21M |
| December 31, 2016 | 176.08M |
| September 30, 2016 | 86.07M |
| June 30, 2016 | 96.09M |
| March 31, 2016 | 87.27M |
| December 31, 2015 | 94.08M |
| September 30, 2015 | 42.09M |
Total Assets Definition
Assets are a main portion of the balance sheet of a company that measure things that provide economic value. A few examples of assets of a company include cash, inventories, and accounts receivable. From an accounting perspective, the balance sheet equation is Assets = Liabilities + Shareholder's Equity.
Total Assets (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Assets (Quarterly) Benchmarks
| Corcept Therapeutics, Inc. | 888.70M |
| Nektar Therapeutics | 1.095B |
| Xeris Biopharma Holdings, Inc. | 411.90M |
| Crinetics Pharmaceuticals, Inc. | 1.322B |
| Alumis, Inc. | 560.62M |
Total Assets (Quarterly) Related Metrics
| Total Liabilities (Quarterly) | 55.11M |
| Shareholders Equity (Quarterly) | 124.58M |
| Debt to Equity Ratio | 0.0149 |
| Current Ratio | 3.462 |
| Net Debt Paydown Yield | 0.02% |